Selective androgen receptor degrader (SARD) ligands and methods of use thereof

A method of treating, suppressing, reducing the incidence of, reducing the severity of, or inhibiting the progression of prostate cancer (PCa) or increasing the survival of a male subject suffering from prostate cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor degrader (SARD) compound represented by the structure of formula I:

• wherein
• T is OH, OR, OCOR, CH3, —NHCOCH3, or NHCOR;
• R1 is CH3, CH2F, CHF2, CF3, CH2CH3, or CF2CF3;
• or T and R1 form a 3-8 carbocyclic or heterocyclic ring;
• Y is H, CF3, F, I, Br, Cl, CN, or C(R)3;
• Z is H, NO2, CN, halide, COOH, COR, NHCOR, CONHR,
• or Y and Z form a 5 to 8 membered fused ring;
• X is CH or N;
• R is H, alkyl, alkenyl, haloalkyl, alcohol, CH2CH2OH, CF3, CH2Cl, CH2CH2Cl, aryl, F, Cl, Br, I, or OH;
• A is R2 or R3;
• R2 is a five-membered saturated or six-membered unsaturated ring having at least one nitrogen atom and 0, 1, or 2 double bonds, optionally substituted with at least one of Q1, Q2, Q3 or Q4, each independently selected from hydrogen, keto, substituted or unsubstituted linear or branched alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, haloalkyl, CF3, substituted or unsubstituted aryl, substituted or unsubstituted phenyl, F, Cl, Br, I, CN, NO2, hydroxyl, alkoxy, OR, benzyl, NCS, maleimide, NHCOOR, N(R)2, NHCOR, CONHR, COOR or COR;
• and
• R3 is halide, N3, CF3, COR4, COCl, COOCOR4, COOR4, OCOR4, OCONHR4, NHCOOR4, NHCONHR4, OCOOR4, CN, CONH2, CONH(R4), CON(R4)2, SR4, SO2R4, SOR4 SO3H, SO2NH2, SO2NH(R4), SO2N(R4)2, NH2, NH(R4), N(R4)2, CO(N-heterocycle), NO2, cyanate, isocyanate, thiocyanate, isothiocyanate, mesylate, tosylate, triflate, PO(OH)2 or OPO(OH)2;
• and
• R4 is H, alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl, wherein said alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl groups are optionally substituted;
• or its optical isomer, isomer, pharmaceutically acceptable salt, pharmaceutical product or any combination thereof;
• wherein if A is Br or I, R1 is CH3, and T is OH, then X is N or the aniline ring forms a fused heterocyclic ring.